The CGEN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CGEN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CGEN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CGEN Detailed Price Forecast - CNN Money||View CGEN Detailed Summary - Google Finance|
|View CGEN Detailed Summary - Yahoo! Finance||View CGEN Stock Research & Analysis - Zacks.com|
|View CGEN Trends & Analysis - Trade-Ideas||View CGEN Major Holders - Barrons|
|View CGEN Call Transcripts - NASDAQ||View CGEN Breaking News & Analysis - Seeking Alpha|
|View CGEN Annual Report - CompanySpotlight.com||View CGEN OTC Short Report - OTCShortReport.com|
|View CGEN Fundamentals - TradeKing||View CGEN SEC Filings - Bar Chart|
|View Historical Prices for CGEN - The WSJ||View Performance/Total Return for CGEN - Morningstar|
|View the Analyst Estimates for CGEN - MarketWatch||View the Earnings History for CGEN - CNBC|
|View the CGEN Earnings - StockMarketWatch||View CGEN Buy or Sell Recommendations - MacroAxis|
|View the CGEN Bullish Patterns - American Bulls||View CGEN Short Pain Metrics - ShortPainBot.com|
|View CGEN Stock Mentions - StockTwits||View CGEN Stock Mentions - PennyStockTweets|
|View CGEN Stock Mentions - Twitter||View CGEN Investment Forum News - Investor Hub|
|View CGEN Stock Mentions - Yahoo! Message Board||View CGEN Stock Mentions - Seeking Alpha|
|View Insider Transactions for CGEN - SECform4.com||View Insider Transactions for CGEN - Insider Cow|
|View CGEN Major Holdings Summary - CNBC||View Insider Disclosure for CGEN - OTC Markets|
|View Insider Transactions for CGEN - Yahoo! Finance||View Institutional Holdings for CGEN - NASDAQ|
|View CGEN Stock Insight & Charts - FinViz.com||View CGEN Investment Charts - StockCharts.com|
|View CGEN Stock Overview & Charts - BarChart||View CGEN User Generated Charts - Trading View|
New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Biotherapeutics, ElectraMeccanica Vehicles, Compugen, and China HGS Real Estate — Consolidated Revenues, Company Growth, and Expectations for 2018
Posted on Friday November 23, 2018
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy
Posted on Tuesday November 13, 2018
HOLON, Israel, Nov. 13, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that a patent for COM902, the Company's TIGIT therapeutic antibody candidate, has been issued by the United States Patent and Trademark Office (USPTO) under the USPTO's Cancer Moonshot Pilot Program providing early examination of patent applications pertaining to cancer immunotherapy. Activating T cells results in stimulating the immune system, and therefore could be used for cancer immunotherapy treatment. This patent as well as other patents the Company is pursuing for COM902 are part of its global patent strategy covering its innovative immuno-oncology pipeline.
Compugen (CGEN) Reports Q3 Loss
Posted on Wednesday November 07, 2018
Compugen (CGEN) delivered earnings and revenue surprises of 58.33% and 0.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Compugen: 3Q Earnings Snapshot
Posted on Wednesday November 07, 2018
The Holon, Israel-based company said it had a loss of 5 cents per share. The drug developer posted revenue of $7.8 million in the period. The company's shares closed at $3.08. A year ago, they were trading ...